Use of cyclophosphamide and other immunosuppressants to treat multiple sclerosis

Multiple Sclerosis Therapeutics

Volumn , Issue , 2007, Pages 481-497

  Gauthier, Susan A ^a   Weiner, Howard L ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 78149471596     PISSN: None     EISSN: None     Source Type: Book    
DOI: None     Document Type: Chapter

References (80)

1. Martin R, McFarland H, McFarlin D. Immunological aspects of demyelinating diseases. Annu Rev Immunol 1992; 10: 153-87
2. Hafler D, Weiner H. Immunologic mechanisms and therapy in multiple sclerosis. Immunol Rev 1995; 144: 75-107
3. Conlon P, Oksenberg J, Zhang J, Steinman L. The immunobiology of multiple sclerosis: an autoimmune disease of the central nervous system. Neurobiol Dis 1999; 6: 149-66
4. Weiner HL. A 21 point unifying hypothesis on the etiology and treatment of multiple sclerosis. Can J Neurol Sci 1998; 25: 93-101
5. Windhagen A, Newcombe J, Dangond F, et al. Expression of co-stimulatory molecules B7-1 (CD80), B7-2 (CD86), and interleukin 12 cytokine in multiple sclerosis lesions. Exp Med 1995; 182: 1985-96
6. Langford C, Klippel J, Balow J, et al. Use of cytotoxic agents and cyclosporine in the treatment of autoimmune disease: Part 1. Rheumatologic and renal diseases. Ann Intern Med 1998; 128: 1021-8
7. Langford C, Klippel J, Balow J, et al. Use of cytotoxic agents and cyclosporine in the treatment of autoimmune disease: Part 2. Inflammatory bowel disease, systemic vasculitis, and therapeutic toxicity. Ann Intern Med 1998; 129: 49-58
8. Aimard G, Girard P, Raveau J. Multiple sclerosis and autoimmunization process. Treatment by antimitotics. Lyons Med 1966; 215: 345-52
9. Girard P, Pellet H. Therapeutique immunodepressive en neurologie. Presse Med 1967; 75: 967-8
10. Millac P, Miller H. Cyclophosphamide in multiple sclerosis. Lancet 1967; 1: 783
11. Cendrowski W. Combined therapeutic trial in multiple sclerosis: hydrocortisone hemisuccinate with cyclophos-phamide or cytosine arabinoside. Acta Neurol Belg 1973; 73: 209-19
12. Drachman D, Paterson P, Schmidt R, Spehlmann R. Cyclophosphamide in exacerbations of multiple sclerosis. Therapeutic trial and a strategy for pilot drug studies. J Neurol Neurosurg Psychiatry 1975; 38: 592-7
13. Hommes O, Prick J, Lamers K. Treatment of the chronic progressive form of multiple sclerosis with a combination of cyclophosphamide and prednisone. Clin Neurol Neurosurg 1975; 78: 59-72
14. Gonsette RE, Demonty L, Delmotte P. Intensive immunosuppression with cyclophosphamide in multiple sclerosis. Follow up of 110 patients for 2-6 years. J Neurol 1977; 214: 173-81
15. Gonsette RE, Demonty L, Delmotte P. Intensive immu-nosuppression with cyclophosphamide in remittent forms of multiple sclerosis: follow-up of 134 patients for 2-10 years. In Bauer HJ, ed. Progress in Multiple Sclerosis Research. Berlin: Springer-Verlag, 1980: 401-06
16. Hommes O, Lamers K, Reekers P. Effect of intensive immunosuppression on the course of chronic progressive multiple sclerosis. J Neurol 1980; 223: 177-90
17. Hommes O, Lamers K, Reekers P. Prognostic factors in intensive immunosuppression on the course of chronic progressive multiple sclerosis. In Bauer HJ, ed. Progress in Multiple Sclerosis Research. Berlin: Springer-Verlag, 1980: 396-400
18. Theys P, Gosseye-Lissior F, Ketelaer P, Carlton H. Short-term intensive cyclophosphamide treatment in multiple sclerosis. A retrospective controlled study. J Neurol 1981; 225: 119-33
19. Hauser S, Dawson D, Lehrich J, et al. Intensive immunosuppression in progressive multiple sclerosis. A randomized, three-arm study of high-dose intravenous cyclophosphamide, plasma exchange, and ACTH. N Engl J Med 1983; 308: 173-80
20. Goodkin D, Plencner S, Palmer-Saxerud J, et al. Cyclophosphamide in chronic progressive multiple sclerosis. Maintenance vs nonmaintenance therapy. Arch Neurol 1987; 44: 823-7
21. Myers L, Fahey J, Moody D, et al. Cyclophos-phamide 'pulses' in chronic progressive multiple sclerosis. A preliminary clinical trial. Arch Neurol 1987; 44: 828-32
22. Siracusa G, Amato M, Fratiglioni L, et al. Short-term intensive cyclophosphamide treatment in progressive multiple sclerosis. Ital J Neurol Sci 1987; 8: 589-92
23. Carter JL, Hafler DA, Dawson DM, et al. Immuno-suppression with high-dose i.v. cyclophosphamide and ACTH in progressive multiple sclerosis: cumulative 6-year experience in 164 patients. Neurology 1988; 38: 9-14
24. Killian J, Bressler R, Armstrong R, Huston D. Controlled pilot trial of monthly intravenous cyclo-phosphamide in multiple sclerosis. Arch Neurol 1988; 45: 27-30
25. Mauch E, Kornhuber H, Pfrommer U, et al. Effective treatment of chronic progressive multiple sclerosis with low dose cyclophosphamide and minor side-effects. Eur Arch Psychiatry Clin Neurosci 1989; 238: 115-17
26. Canadian Cooperative Multiple Sclerosis Study Group. The Canadian cooperative trial of cyclophosphamide and plasma exchange in progressive multiple sclerosis. Lancet 1991; 337: 441-6
27. Trouillas P, Neuschwander P, Nighoghossian N, et al. Intensive immunosuppression in progressive multiple sclerosis. An open study comparing 3 groups: cyclophosphamide, cyclophosphamide-plasmaphoresis, and control subjects. Results after 3 years. Rev Neurol 1989; 145: 369-77
28. Millefiorini E, Di Giovanni M, Bernardi S, et al. 24-month follow-up of multiple sclerosis patients treated with cyclophosphamide. Ital J Neurol Sci 1990; 11: 605-7
29. D'Andrea F, D'Aurizio C, Marini C, Prencipe M. Cyclophosphamide in relapsing-remitting multiple sclerosis. Ital J Neurol Sci 1990; 11: 271-4
30. Likosky W, Fireman B, Elmore R, et al. Intense immunosuppression in chronic progressive multiple sclerosis: the Kaiser study. J Neurol Neurosurg Psychiatry 1991; 54: 1055-60
31. Weiner HL, Mackin GA, Orav EJ, et al. Intermittent cyclophosphamide pulse therapy in progressive multiple sclerosis: final report of the Northeast Cooperative Multiple Sclerosis Treatment Group. Neurology 1993; 43: 910-18
32. Weinstock-Guttman B, Kinkel R, Cohen JA. Treatment of fulminant multiple sclerosis with intravenous cyclo-phosphamide. Neurologist 1997; 3: 178-85
33. Gobbini M, Smith M, Richert N, et al. Effect of open label pulse cyclophosphamide therapy on MRI measures of disease activity in five patients with refractory relapsing- remitting multiple sclerosis. J Neuroimmunol 1999; 99: 142-9
34. Hohol M, Olek M, Orav E, et al. Treatment of progressive multiple sclerosis with pulse cyclophos-phamide/methylprednisolone: response to therapy is linked to the duration of progressive disease. Mult Scler 1999; 5: 403-9
35. Manova MG, Kostadinova II, Rangelov AA. Clinico-laboratory study of methylprednisolone and cyclo-phosphamide treatment in patients with multiple sclerosis relapse. Folla Med (Plovdiv) 2000; 42: 20-5
36. Patti F, Cataldi M, Nicoletti F, et al. Combination of cyclophosphamide and interferon-beta halts progression in patients with rapidly transitional multiple sclerosis. J Neurol Neurosurg Psychiatry 2001; 71: 404-7
37. Patti F, Reggio E, Palermo F, et al. Stabilization of rapidly worsening multiple sclerosis for 36 months in patients treated with interferon beta plus cyclophos-phamide followed by interferon beta. J Neurol 2004; 251: 1502-6
38. Zephir H, De Seze J, Duhamel A, et al. Treatment of progressive forms of multiple sclerosis by cyclophos-phamide: a cohort study of 490 patients. J Neurol Sci 2004; 218: 73-7
39. Khan O, Zvartau-Hind M, Caon C, et al. Effect of monthly intravenous cyclophosphamide in rapidly deteriorating multiple sclerosis patients resistant to conventional therapy. Mult Scler 2001; 7: 185-8
40. Perini P, Gallo P. Cyclophosphamide is effective in stabilizing rapidly deteriorating secondary progressive multiple sclerosis. J Neurol 2003; 250: 834-8
41. Reggio E, Nicoletti A, Fiorilla T, et al. The combination of cyclophosphamide plus interferon beta as rescue therapy could be used to treat relapsing-remitting multiple sclerosis patients. Twenty-four months follow-up. J Neurol 2005; 252: 1255-61
42. Zephir H, De Seze J, Dujardin K, et al. One-year cyclophosphamide treatment combined with methy-prednisolone improves cogitive dysfuntion in progressive forms of multiple sclerosis. Mult Scler 2005; 11: 360-3
43. Smith DR, Weinstock-Guttman B, Cohen JA, et al. A randomized blinded trial of combination therapy with cyclophosphamide in patients with active multiple sclerosis on interferon beta. Mult Scler 2005; 11: 573-82
44. Weiner H, Cohen J. Treatment of multiple sclerosis with cyclophosphamide: critical review of clinical and immunologic effects. Mult Scler 2002; 8: 142-54
45. Wieczorek VL, Brodkorb W. Erfahrungen mit der immunosuppressive Behandlung der Multiplen Sklerose mit Cyclophamid und Imuran. Dtsch Ges Wesen 1971; 26: 1791-4
46. Gopel W, Benkenstein H, Banzhaf M. Immunosup-pressive therapy of multiple sclerosis using cyclophos-phamide and Imuran. Report on 57 cases. Dtsch Gesundheitsw 1972; 27: 1955-61
47. Noseworthy J, Ebers G, Roberts R. Cyclophosphamide and MS. Neurology 1994; 44: 579-81
48. Weiner HL, Dawson DM, Hafler DA, et al. Cyclophosphamide and plasma exchange in multiple sclerosis. Lancet 1991; 337: 1033-4
49. Noseworthy J, Vandervoort M, Penman M, et al. Cyclophosphamide and plasma exchange in multiple sclerosis. Lancet 1991; 337: 1540-1
50. Patti F, Amato M, Filippi M, et al. A double blind, placebo-controlled, phase II, add-on study of cyclophosphamide (CTX) for 24 months in patients affected by multiple sclerosis on a background therapy with interferon-beta study denomination: CYCLIN. J Neurol Sci 2004; 223: 69-71
51. Paterson P, Drobish D. Cyclophosphamide: effect on experimental allergic encephalomyelitis in Lewis rats. Science 1969; 165: 191-2
52. Comabella M, Balashov K, Issazadeh S, et al. Elevated interleukin-12 in progressive multiple sclerosis correlates with disease activity and is normalized by pulse cyclophosphamide therapy. J Clin Invest 1998; 102: 671-8
53. Smith D, Balashov KE, Hafler DA, et al. Immune deviation following pulse cyclophosphamide/methylpred-nisolone treatment of multiple sclerosis: increased interleukin-4 production and associated eosinophilia. Ann Neurol 1997; 42: 313-18
54. Karni A, Balashov K, Hancock W, et al. Cyclo-phosphamide modulates CD4(+) T cells into a T helper type 2 phenotype and reverses increased IFN-gamma production of CD8(+) T cells in secondary progressive multiple sclerosis. J Neuroimmunol 2004; 146: 189-98
55. Wender M, Tokarz E, Michalowska G, Wajgt A. Therapeutic trials of multiple sclerosis and intrathecal IgG production. Ital J Neurol Sci 1986; 7: 205-8
56. Moody D, Fahey J, Grable E, et al. Administration of monthly pulses of cyclophosphamide in multiple sclerosis patients. Delayed recovery of several immune parameters following discontinuation of long-term cyclophosphamide treatment. J Neuroimmunol 1987; 14: 175-82
57. Moody D, Kagan J, Liao D, et al. Administration of monthly-pulse cyclophosphamide in multiple sclerosis patients. Effects of long-term treatment on immuno-logic parameters. J Neuroimmunol 1987; 14: 161-73
58. Hafler D, Orav J, Gertz R, et al. Immunologic effects of cyclophosphamide/ACTH in patients with chronic progressive multiple sclerosis. J Neuroimmunol 1991; 32:149-58
59. Mickey M, Ellison G, Fahey J, et al. Correlation of clinical and immunological states in multiple sclerosis. Arch Neurol 1987; 44: 371-5
60. Takashima H, Smith DR, Fukaura H, et al. Pulse cyclophosphamide plus methylprednisolone induces myelin-antigen-specific IL-4-secreting T cells in multiple sclerosis patients. Clin Immunol Immunopathol 1998; 88: 28-34
61. Hommes O, Aerts F, Bahr U, Schulten H. Cyclo-phosphamide levels in serum and spinal fluid of multiple sclerosis patients treated with immunosup-pression. J Neurol Sci 1983; 58: 297-303
62. Bahr U, Hommes O, Aerts F. Determination of cyclophosphamide in urine, serum, and cerebrospinal fluid of multiple sclerosis patients by field desorption spectrometry. Clin Chim Acta 1980; 103: 183-92
63. Lamers K, Uitdehaag B, Hommes O, et al. The shortterm effect of an immunosuppressive treatment on CSF myelin basic protein in chronic progressive multiple sclerosis. J Neurol Neurosurg Psychiatry 1988; 51: 1334-7
64. Portaccio E, Zipoli V, Siracusa G, et al. Safety and tol-erability of cyclophosphamide 'pulses' in multiple sclerosis: a prospective study in a clinical cohort. Mult Scler 2003; 9: 446-50
65. Boumpas D, Austin H, Vaughan E, et al. Risk for sustained amenorrhea in patients with systemic lupus erythematosus receiving intermittent pulse cyclophos-phamide therapy. Ann Intern Med 1993; 119: 366-9
66. Gourley M, Austin H, Scott D, et al. Methyl-prednisolone and cyclophosphamide, alone or in combination, in patients with lupus nephritis. A randomized, controlled trial. Ann Intern Med 1996; 125: 549-71
67. Moore MJ. Clinical pharmacokinetics of cyclophos-phamide. Clin Pharmacokinet 1991; 20: 194-208
68. Radis C, Kahl L, Baker G, et al. Effects of cyclophos-phamide on the development of malignancy and on long-term survival of patients with rheumatoid arthritis. A 20-year followup study. Arthritis Rheum 1995; 38: 1120-7
69. Talar-Williams C, Hijazi YM, Walther MM, et al. Cyclophosphamide-induced cystitis and bladder cancer in patients with Wegener granulomatosis. Ann Intern Med 1996; 124: 477-84
70. Goodkin D, Rudick R, VanderBrug-Medendorp S, et al. Low-dose (7.5 mg) oral methotrexate reduces the rate of progression in chronic progressive multiple sclerosis. Ann Neurol 1995; 37: 30-40
71. Calabresi P, Wilterdink J, Rogg J, et al. An open-label trial of combination therapy with interferon beta-1a and oral methotrexate in MS. Neurology 2002; 58: 314-17
72. Yudkin PL, Ellison GW, Ghezzi A, et al. Overview of azathioprine treatment in multiple sclerosis. Lancet 1991; 338: 1051-5
73. Lus G, Romano F, Scuotto A, et al. Azathioprine and interferon beta(1a) in relapsing-remitting multiple sclerosis patients: increasing efficacy of combined treatment. Eur Neurol 2004; 51: 15-20
74. Fernandez O, Guerrero M, Mayorga C, et al. Combination therapy with interferon beta-1b and aza-thioprine in secondary progressive multiple sclerosis. A two-year pilot study. J Neurol 2002; 249: 1058-62
75. Markovic-Plese S, Bielekova B, Kadom N, et al. Longitudinal MRI study: the effects of azathioprine in MS patients refractory to interferon beta-1b. Neurology 2003; 60: 1849-51
76. Pulicken M, Bash CN, Costello K, et al. Optimization of the safety and efficacy of interferon-beta 1b and azathioprine combination therapy in multiple sclerosis. Mult Scler 2005; 11: 169-74
77. Ahrens N, Salama A, Haas J. Mycophenolate-mofetil in the treatment of refractory multiple sclerosis. J Neurol 2001; 248: 713-14
78. Frohman E, Brannon K, Racke M, Hawker K. Mycophenolate mofetil in multiple sclerosis. Clin Neuropharmacol 2004; 27: 80-3
79. Vukusic S, Ducray F, Gignoux L, et al. Myco-phenolate mofetil: an open-label study in 42 MS patients. Presented at the 56th Annual Meeting of the American Academy of Neurology, San Francisco, CA, May 2004: abstr
80. Vermersch P, Waucquier N, Bourteel H, et al. Treatment of multiple sclerosis with a combination of interferon beta-1a (Avonex) and mycophenolate mofetil (CellCept): results of a phase II clinical trial. Presented at the 56th Annual Meeting of the American Academy of Neurology, San Francisco, CA, May 2004: abstr